Research location
Holstebro
Denmark
Advertisement
Research activity in Holstebro
DenmarkCureCurrent currently publishes aggregate city-level research activity for this location: 45 trials and 46 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Holstebro
45 linked trials · page 1 of 1The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on DialysisNCT03862859 · 2019-10-09 · 1 site observation
RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD ParticipantsNCT05013008 · 2021-08-18 · 1 site observation
COMPLETED
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisNCT04688788 · 2021-04-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641 · 2020-09-24 · 1 site observation
COMPLETED
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)NCT04458051 · 2020-08-13 · 1 site observation
COMPLETED
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)NCT04477707 · 2020-07-23 · 1 site observation
COMPLETED
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)NCT04410978 · 2020-06-30 · 1 site observation
COMPLETED
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate CancerNCT04114825 · 2019-11-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer ParticipantsNCT02813408 · 2016-05-03 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseNCT02540993 · 2015-09-17 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseaseNCT02545049 · 2015-09-17 · 1 site observation
COMPLETED
Lung Protective Ventilation During Robotic Assisted ProstatectomyNCT02551341 · 2015-09-01 · 1 site observation
COMPLETED
Xbox Kinect Training in Men With Prostate CancerNCT01762241 · 2015-02-01 · 1 site observation
COMPLETED
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.NCT02296138 · 2015-01-13 · 1 site observation
COMPLETED
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic NephropathyNCT01874431 · 2013-06-12 · 1 site observation
COMPLETED
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney DiseaseNCT01752985 · 2013-03-18 · 1 site observation
TERMINATED
Optimal Dietary Treatment of Obese AdultsNCT01685957 · 2012-10-01 · 1 site observation
COMPLETED
The Effects of Nebivolol on the NO-system in Patients With Essential HypertensionNCT01679652 · 2012-08-01 · 1 site observation
COMPLETED
Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive HormonesNCT01617551 · 2012-03-01 · 1 site observation
UNKNOWN
Hydroxyethyl Starch and Renal Function After Radical ProstatectomyNCT01486563 · 2012-01-01 · 1 site observation
COMPLETED
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerNCT01322490 · 2011-11-28 · 1 site observation
COMPLETED
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.NCT01405872 · 2011-09-01 · 1 site observation
COMPLETED
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGONNCT01234350 · 2011-01-01 · 1 site observation
COMPLETED
Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical PracticeNCT01228682 · 2010-10-01 · 1 site observation
UNKNOWN
The Effect of Amiloride and Spironolactone in Patients With HypertensionNCT01388088 · 2010-09-01 · 1 site observation
COMPLETED
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular VariablesNCT01195805 · 2010-08-01 · 1 site observation
COMPLETED
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and NephropathyNCT01208701 · 2010-05-01 · 1 site observation
COMPLETED
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsNCT00884273 · 2009-08-01 · 1 site observation
COMPLETED
The Effect of Amiloride and Spironolactone in Healthy PersonsNCT00857909 · 2009-01-01 · 1 site observation
COMPLETED
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00722267 · 2008-07-01 · 1 site observation
COMPLETED
CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.NCT00714038 · 2008-05-01 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone DiseaseNCT00558272 · 2008-02-01 · 1 site observation
COMPLETED
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate CancerNCT00626548 · 2008-01-01 · 1 site observation
TERMINATED
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.NCT00563381 · 2008-01-01 · 1 site observation
COMPLETED
The Acute Effect of Atorvastain on Renal Function in Patients With Type II DiabetesNCT00678522 · 2007-09-01 · 2 site observations
COMPLETED
The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential HypertensionNCT00438945 · 2007-01-01 · 1 site observation
COMPLETED
Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep ApneaNCT00438412 · 2006-10-01 · 1 site observation
SUSPENDED
Glucose in Dialysis Water in Diabetics With Chronic Renal FailureNCT00438503 · 2006-05-01 · 1 site observation
COMPLETED
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential HypertensionNCT00345124 · 2006-05-01 · 1 site observation
COMPLETED
A Comparison of Telemedical and Conventional Antihypertensive TreatmentNCT00282334 · 2004-05-01 · 1 site observation
COMPLETED
STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFENCT00278057 · 2003-05-01 · 1 site observation
COMPLETED
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD PatientsNCT00144339 · 2002-12-01 · 1 site observation
COMPLETED
Heart Rate Variability in White Coat Hypertension and Essential HypertensionNCT00286884 · 1 site observation
COMPLETED
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)NCT00313976 · 1 site observation
WITHDRAWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.